In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials

Psychopharmacology, Journal Year: 2024, Volume and Issue: 241(6), P. 1101 - 1110

Published: April 29, 2024

Language: Английский

---

Psychopharmacological interaction of alcohol and posttraumatic stress disorder: Effective action of naringin

European Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 978, P. 176791 - 176791

Published: June 27, 2024

Language: Английский

---

State of the Science: Treatment of comorbid posttraumatic stress disorder and substance use disorders

Journal of Traumatic Stress, Journal Year: 2024, Volume and Issue: 37(6), P. 803 - 813

Published: June 10, 2024

Abstract Posttraumatic stress disorder (PTSD) and substance use disorders (SUDs) co‐occur at high rates, with research showing that up to nearly 60% of individuals PTSD also suffer from an alcohol and/or drug disorder. PTSD/SUD is complex; associated adverse health, social, economic outcomes; can be challenging treat. Over the past decade, landscape treatment addressing has significantly expanded. Ongoing efforts aimed developing evaluating novel treatments for PTSD/SUD, encompassing both psychotherapy pharmacotherapy approaches, are steadily advancing. As such, this State Science paper reviews literature on latest scientific advances in treating PTSD/SUD. Clinical practice guidelines discussed, along evidence‐based psychotherapies emerging interventions. Rigorously conducted clinical trials demonstrate individual, manualized, trauma‐focused most efficacious among Moreover, patients do not need abstinent initiate or benefit treatment. To date, no medications have been established comorbidity. We highlight ongoing such as new forms integrated psychotherapies, pharmacological augmentation strategies, technology‐based enhancements. Finally, promising future directions field discussed.

Language: Английский

---

Design and Methodology of the First Open-Label Trial of MDMA-Assisted Therapy for Veterans with Post-Traumatic Stress Disorder and Alcohol Use Disorder: Considerations for a Randomized Controlled Trial

Contemporary Clinical Trials Communications, Journal Year: 2024, Volume and Issue: 41, P. 101333 - 101333

Published: July 20, 2024

Posttraumatic stress disorder and alcohol use (PTSD, AUD) commonly co-occur are associated with more severe symptomatology than either alone, increased risk of suicide, poorer response to existing treatments. A promising therapeutic intervention is the integration 3,4-methylenedioxymethamphetamine (MDMA) psychotherapy. The Federal Drug Administration (FDA) designated MDMA assisted therapy (MDMA-AT) as a Breakthrough Therapy for PTSD based on results from six Phase 2 clinical trials. Case data first study evaluating MDMA-AT AUD found treatment was well tolerated significantly reduced post treatment. This manuscript reports premise, design, methodology open-label trial military veterans (N=12) AUD. Neuroimaging biomarker included evaluate brain changes, neuroinflammation, pre-post component (comorbidity) regulatory processes (Schedule I drug) setting up this long complex. research community will benefit work establish common outcomes, standardized protocols, assessments FDA approval. NCT05943665

Language: Английский

---

The Future of Alcohol Use Disorder Treatment and Research

Psychiatry update, Journal Year: 2024, Volume and Issue: unknown, P. 189 - 203

Published: Jan. 1, 2024

Language: Английский

---